Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 2/20 | 0.43 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | MC4R | P32245 | 1/20 | 0.39 |
| ▸ | CHKA | P35790 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | F11 | P03951 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20548795 | 0.83 | SIGMAR1 (0.44) | LPLLIPGSIGMAR1LMNAALDH1A1 | |
| SCHEMBL3663917 | 0.82 | ENPP2 (0.46) | LPLLIPGSIGMAR1ALDH1A1KMT2A | |
| SCHEMBL2320439 | 0.81 | LMNA (0.61) | LPLLIPGLMNAALDH1A1HRH3 | |
| SCHEMBL27934011 | 0.81 | ALDH1A1 (0.62) | LPLLIPGSIGMAR1LMNAALDH1A1 | |
| SCHEMBL4591222 | 0.81 | DRD4 (0.50) | SIGMAR1LMNAALDH1A1POLBHRH3 | |
| SCHEMBL28440571 | 0.81 | LMNA (0.53) | LMNAALDH1A1HRH3CA2MC4R | |
| Hydrochloric Acid SCHEMBL21747953 | 0.80 | LMNA (0.59) | LPLLIPGLMNAALDH1A1HRH3 | |
| SCHEMBL2234131 | 0.80 | LMNA (0.46) | SIGMAR1LMNAALDH1A1POLBHRH3 | |
| SCHEMBL25860058 | 0.80 | ALDH1A1 (0.65) | LMNAALDH1A1POLBKMT2A | |
| SCHEMBL2557827 | 0.79 | HRH3 (0.65) | ALDH1A1POLBHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2242742-B1 | PYRIDINE DERIVATIVES | NOVARTIS AG (CH) | 2015-12-02 | — | — | EP | disclosed |
| US-8343966-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-01-01 | — | — | US | disclosed |
| EP-2242742-A2 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2010-10-27 | — | — | EP | disclosed |
| US-20090215776-A1 | Organic compounds | ADCOCK CLAIRE | 2009-08-27 | — | — | US | disclosed |
| WO-2009087212-A2 | PYRIDINE DERIVATIVES | NOVARTIS AG (CH) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215776-A1 | Organic compounds | REN, RXFP1, MYLK | LPL 4007/4885LIPG 3539/4885SIGMAR1 243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.